Edition:
India

Monsanto Co (MON.N)

MON.N on New York Stock Exchange

102.20USD
30 Sep 2016
Change (% chg)

$0.41 (+0.40%)
Prev Close
$101.79
Open
$102.28
Day's High
$102.47
Day's Low
$101.60
Volume
1,425,749
Avg. Vol
875,860
52-wk High
$113.20
52-wk Low
$83.73

MON.N

Chart for MON.N

About

Monsanto Company (Monsanto), along with its subsidiaries, is a provider of agricultural products for farmers. The Company provides seeds, biotechnology trait products, herbicides and precision agriculture tools to farmers. The Company operates through two segments: Seeds and Genomics, and Agricultural Productivity. Through its... (more)

Overall

Beta: 1.18
Market Cap(Mil.): $44,720.22
Shares Outstanding(Mil.): 437.58
Dividend: 0.54
Yield (%): 2.11

Financials

Monsanto ally Novozymes sees opportunity, risk in Bayer merger

LONDON Novozymes , already grappling with the consequences of low oil and crop prices, is watching anxiously to see what Bayer's purchase of Monsanto will mean for the Danish group's ties with its key agricultural partner.

28 Sep 2016

INTERVIEW-Monsanto ally Novozymes sees opportunity, risk in Bayer merger

LONDON, Sept 28 Novozymes, already grappling with the consequences of low oil and crop prices, is watching anxiously to see what Bayer's purchase of Monsanto will mean for the Danish group's ties with its key agricultural partner.

28 Sep 2016

BRIEF-Monsanto announces global licensing agreement with Broad Institute

* Monsanto announces global licensing agreement with Broad Institute on key genome-editing application

22 Sep 2016

BRIEF-Monsanto Co - Bayer is committed to make divestitures to obtain antitrust approvals

* Bayer is committed to make divestitures if required up to $1.6 billion to obtain antitrust approvals for merger

21 Sep 2016

BRIEF-Monsanto Co - Bayer not required to take any material adverse divestiture action

* Bayer not required to take any divestiture action that would likely result in 1-year loss of net sales to Bayer, co in excess of $1.6 billion

21 Sep 2016

Bayer raises sales targets for top-selling drugs after Monsanto deal

FRANKFURT German drugmaker Bayer said its two best-selling drugs had a higher annual peak sales potential than previously targeted, after the agreed $66 billion takeover of Monsanto stirred criticism it might neglect its pharmaceuticals business.

20 Sep 2016

Bayer ups sales targets for top-selling drugs after Monsanto deal

FRANKFURT German drugmaker Bayer said its two best-selling drugs had a higher annual peak sales potential than previously targeted, after the agreed $66 billion takeover of Monsanto stirred criticism it might neglect its pharmaceuticals business.

20 Sep 2016

Bayer ups sales targets for top-selling drugs after Monsanto deal

FRANKFURT, Sept 20 German drugmaker Bayer said its two best-selling drugs had a higher annual peak sales potential than previously targeted, after the agreed $66 billion takeover of Monsanto stirred criticism it might neglect its pharmaceuticals business.

20 Sep 2016

BRIEF-Fitch says Bayer, Monsanto deal structure reflects financial risks

* fitch: bayer, monsanto deal structure reflects financial risks

15 Sep 2016

BRIEF-S&P downgrades Monsanto to 'BBB' on weak operations

* S&P - Monsanto Co. downgraded to 'BBB' on weak operations; Ratings on creditwatch positive on planned acquisition by Bayer AG

15 Sep 2016

Earnings vs. Estimates